Loading clinical trials...
Loading clinical trials...
Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme
Conditions
Locations
19
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
UC Davis
Sacramento, California, United States
University of Miami
Miami, Florida, United States
Northwestern University
Chicago, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
November 30, 2016
Primary Completion Date
November 30, 2022
Completion Date
November 30, 2022
Last Updated
February 13, 2023
NCT05969860
NCT02800486
NCT05789394
NCT06934889
NCT06860594
NCT00083512
Lead Sponsor
University of Iowa
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions